← Back to Bills
S. 4152Senate117th Congress (2021-2023)In Committee

A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Sponsored by Mark KellySen. Mark Kelly (D-AZ)
Introduced May 5, 2022

AI-Generated Summary

Updated February 8, 2026 at 11:09 AM UTC

The bill amends the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public‑Private Partnerships program. It raises the annual funding level to $10 million for each fiscal year from 2023 through 2027, extending the program’s support beyond the previous 2018‑2022 period. This affects the FDA’s collaborative efforts with industry and other partners aimed at accelerating the development of medical products.

Key Provisions

  • Changes the authorized funding for the Critical Path Public‑Private Partnerships from $6 million per year (FY 2018‑2022) to $10 million per year (FY 2023‑2027).
  • Extends the reauthorization period of the program to cover fiscal years 2023 through 2027.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
SenateIntro Referral Latest Action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Health, Education, Labor, and Pensions Committee

May 5, 2022

View full timeline
SenateIntro Referral

Introduced in Senate

May 5, 2022

SenateIntro Referral

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Health, Education, Labor, and Pensions Committee

May 5, 2022

Bill Text

Latest available legislative text

Reading Mode
Latest
Raw Text PDF XML
Introduced in SenateIssued May 5, 2022

II

117th CONGRESS

2d Session

S. 4152

IN THE SENATE OF THE UNITED STATES

May 5, 2022

Mr. Kelly (for himself, Ms. Collins, and Ms. Sinema) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

1.

Reauthorization of the Critical Path Public-Private Partnerships

Section 566(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–5(f)) is amended by striking $6,000,000 for each of fiscal years 2018 through 2022 and inserting $10,000,000 for each of fiscal years 2023 through 2027.